For R&D Executives Who Received A Full Year Of Salary, 164 Companies

For CFOs Who Received A Full Year Of Salary, 210 Companies

For CEOs Who Received A Full Year Of Salary, 244 Companies

For CEOs Who Received A Full Year Of Salary, 244 Companies

For CEOs Who Received A Full Year Of Salary, 244 Companies

For CEOs Who Received A Full Year Of Salary, 244 Companies

For CEOs Who Received A Full Year Of Salary, 244 Companies

Company Name of Executive Base Salary ($000) Bonus ($000) Total ($000) Other ($000) Long-Term Comp. ($000) Total Direct Comp. ($000) Potential Realizable Value of Option Grants ($000) FYE Value of Exercisable In-the-Money Options ($000) Aastrom Biosciences Inc.** Brian S. Hampson 188 25 213 0 0 213 184 6 Abgenix Inc. Gayle M. Mills 233 78 311 7 0 318 316 55 Accelrys Inc.*^ Mahesh Krishnamurthy (1) 235 47 282 7 0 289 140 0 Acusphere Inc. Charles P. Cox

For The 65 Business And Corporate Officers In BioWorld's 264-Company Survey Who Received A Full Year Of Compensation Rank Name of Executive Company Base Salary ($000) Bonus ($000) Total ($000) 1 United Therapeutics Corp. Fred T. Hadeed 500 125 625 2 Lifecell Corp. Paul G. Thomas 370 250 620 3 Connetics Corp. John L. Higgins 315 208 523 4 Theravance Inc. Marty Glick 324 195 520 5 Incyte Corp. John A. Keller (9) 310 186 496 6 Biomarin Pharmaceutical Inc. Emil

Company Name of Executive Base Salary ($000) Bonus ($000) Total ($000) Other ($000) Long-Term Comp. ($000) Total Direct Comp. ($000) Potential Realizable Value of Option Grants ($000) FYE Value of Exercisable In-the-Money Options ($000) Adolor Corp. Martha E. Manning 253 44 297 4 0 301 644 0 Affymetrix Inc. Barbara A. Caulfield 365 496 861 15 0 877 537 4,819 Alexion Pharmaceuticals Inc. Thomas I.H. Dubin 218 33 251 5 0 256 247 15 Alkermes Inc.*^ Kathryn L

For The 75 Legal Officers In BioWorld's 264-Company Survey Who Received A Full Year Of Compensation Rank Name of Executive Company Base Salary ($000) Bonus ($000) Total ($000) 1 Peter Wirth Genzyme Corp. 625 455 1,080 2 Barbara A. Caulfield Affymetrix Inc. 365 496 861 3 John E. Osborn Cephalon Inc. 382 305 687 4 Paul A. Mahon United Therapeutics Corp. 500 100 600 5 Bradford W. Middlekauff Medarex Inc. 362 201 563 6 Barry J. Buzogany Invitrogen Corp. 323

Company Name of Executive Base Salary ($000) Bonus ($000) Total ($000) Other ($000) Long Term Comp. ($000) Total Direct Comp. ($000) Potential Realizable Value of Option Grants ($000) FYE Value of Exercisable In-the-Money Options ($000) Abgenix Inc. C. Geoffrey Davis 277 66 344 1 1,285 1,630 168 545 Acadia Pharmaceuticals Inc. Robert E. Davis 237 71 309 0 621 930 121 221 Access Pharmaceuticals Inc. David P. Nowotnik 239 0 239 6 0 245 92 181 Acusphere Inc

For The 146 R&D Executives In BioWorld's 264-Company Survey Who Received A Full Year Of Compensation Rank Name of Executive Company Base Salary ($000) Bonus ($000) Total ($000) 1 Roger M. Perlmutter Amgen Inc. 794 1,460 2,254 2 Norbert W. Bischofberger Gilead Sciences Inc. 535 466 1,001 3 James F. Young MedImmune Inc. 546 400 946 4 George D. Yancopoulos Regeneron Pharmaceuticals Inc. 496 274 770 5 Burt A. Adelman (5) Biogen Idec Inc. 446 289 734 6 Craig A

Company Name of Executive Base Salary ($000) Bonus ($000) Total ($000) Other ($000) Long-Term Comp. ($000) Total Direct Comp. ($000) Potential Realizable Value of Option Grants ($000) FYE Value of Exercisable In-the-Money Options ($000) Aastrom Biosciences Inc.** Alan M. Wright 206 10 216 0 0 216 224 27 Acadia Pharmaceuticals Inc. Thomas H. Aasen 232 78 310 0 147 456 121 841 Accelrys Inc. John J. Hanlon (1) 233 50 283 98 0 382 0 57 Access Pharmaceuticals

For The 197 CFOs In BioWorld's 264-Company Survey Who Received A Full Year Of Compensation Rank Name of Executive Company Base Salary ($000) Bonus ($000) Total ($000) 1 Richard D. Nanula Amgen Inc. 695 1,095 1,790 2 Robert J. Hugin Celgene Corp. 539 388 927 3 Michael S. Wyzga Genzyme Corp. 430 463 893 4 John F. Milligan Gilead Sciences Inc. 442 388 830 5 Peter N. Kellogg Biogen Idec Inc. 490 328 818 6 Louis J. Lavigne Jr. (25) Genentech Inc. 412 395 807

Rank Name of Executive Company Potential Realizable Value of Option Grants # ($000) No. of Securities Under-Lying Options ($000) % of Total Options Granted To Employees (%) Exercise or Base Price ($/Share)## Stock Price 12/31/04 ($) 1 John C. Martin Gilead Sciences Inc. 16,320 850 6.87 30.53 34.99 2 Henri A. Termeer Genzyme Corp. 12,700 460 5.36 43.9 58.07 3 Arthur D. Levinson Genentech Inc. 11,900 900 4.31 53.23 54.44 4 Howard H. Pien Chiron Corp. 11,441 350

Rank Name of Executive Age Company FYE Value of Exercisable In-the-Money Options ($000) Total No. of Shares Owned By CEO # Percent of Co. Stock Owned By CEO ## (%) Stock Price 12/31/03 Stock Price 12/31/04 ($) Percent Change Stock Price (%) 1 Arthur D. Levinson 55 Genentech Inc. 133,108 4,074,269 * 46.79 54.44 16.3 2 John C. Martin 53 Gilead Sciences Inc. 92,540 4,351,078 1 29.14 34.99 20.1 3 Timothy J. Barberich 57 Sepracor Inc. 75,639 2,709,127 2.6 23.93

Company Name of Executive Age Base Salary ($000) Bonus ($000) Total ($000) Other ($000) Long-term Compensation ($000) Total Direct Compensation ($000) Base Salary Prior FY ($000) Percent Change Base Salary (%) Potential Realizable Value of Option Grants ($000) FTE Value of Exercisable In-the-Money Options ($000) Percent of Co. Stock Owned By CEO (%) Stock Price 12/31/03 ($) Stock Price 12/31/04 ($) Percent Change Stock Price (%) Shares Out ($M) Approx. Long-Term Mkt. Cap. 12/31

CEOs Whose Total Direct Compensation Exceeded $2 Million Name of Executive Company Base Salary ($000) Bonus ($000) Other ($000) Long-Term Compensation ($000) Total Direct Compensation ($000) Arthur D. Levinson Genentech Inc. 894 1,310 126 41,157 43,487 Henry Linsert Jr. Martek Biosciences Corp. 440 165 3 28,473 29,080 John C. Martin Gilead Sciences Inc. 870 1,021 13 13,214 15,118 Timothy J. Barberich Sepracor Inc. 476 191 9 13,503 14,179 James C. Mullen (1